Clinical observation of Weichangan pills combined with living intestinal bacteria preparation on post-infection irritable bowel syndrome
-
摘要: [目的]探讨胃肠安联合肠道活菌制剂治疗感染后肠易激综合征腹泻型的临床疗效。[方法]将76例感染后肠易激综合征腹泻型患者，随机分为2组，每组各38例。治疗组口服胃肠安丸0.1 g，3次/d；复方嗜酸乳杆菌片1 g，3次/d；马来酸曲美布汀片0.2 g，3次/d。对照组口服马来酸曲美布汀片0.2 g，3次/d。在连续治疗第2周和第4周对患者大便次数和临床症状进行疗效评估，并观察不良反应。[结果]治疗第2周和第4周2组的临床疗效比较，差异均有统计学意义（P<0.05）。[结论]胃肠安丸联合肠道活菌制剂治疗感染后肠易激综合征腹泻型疗效显著，值得临床推广。Abstract: [Objective] To explore the clinical effects of the therapeutic regimen Weichangan pills combined with living intestinal bacteria preparation on post-infection irritable bowel syndrome(PI-IBS).[Methods] Seventy-six patients of PI-IBS were randomly assigned into two groups. The treatment group was administered as follows:Weichangan pills 0.1 g, po, tid.Eosinophil-Lactobacillus Compound tablets, 1 g, po, tid, and Trimebutine Maleate tablets 0.2 g, po, tid, While the control group was only administered Trimebutine Maleate tablets 0.2 g, po, tid.The clinical evaluations including fecal frequency, clinical symptoms and side effects were undertaken after 2 and 4 weeks' treatments.[Results] Significant differences were observed in clinical evaluations after 2 and 4 weeks' treatments(P<0.05).[Conclusion] The therapeutic regiment Weichangan pills combined with living intestinal bacteria preparation on post-infection irritable bowel syndrome(PI-IBS) is effective in clinical evaluation, which is worthwhile for clinical application.
-
-
[1] THABANE M, MARRSHALL J K.Post infectious irritable bowel syndrome[J].世界胃肠病学杂志(英文版), 2009, 15:3591-3596.
[2] SPILLER R, GARSED K.Postinfectious irritable bowel syndrome[J].Gastroenterology, 2009, 136:1979-1988.
[3] MARSHALL J K, THABANE M, GARG A X, et al.Walkerton health study investigators.Eight year prognosis of postifectious irritable bowel syndrome following waterborne bacterial dysentery[J].Gut, 2010, 59:605-611.
[4] POKKUNURI V, PIMENTEL M, MORALES W, et al.Role of cytolethal distending toxin in altered stool form and bowel phenotypes ins rat model of postinfectious irritable bowel syndrome[J].Neurogastro enterol Motil, 2012, 18:434-442.
[5] CHEN J, ZHANG Y, DENG Z.Imbalanced shift of cytokine expression between T helper 1 and T helper 2(Th1/Th2)in intestinal mucosa of patients with Postinfectious irritable bowel syndrome[J].BMC Gastroenterol, 2012, 12:91-91.
[6] QIN H Y, XIAO H T, LEUNG F P, et al.JCM-16021, a chiese herbal formula, altenuated visceral hyperalgesia in tnbs-induced postinflammatory irritable bowel syndrome through reducing colcnicec cell hyperplasia and serotonin availability in rats[J].Ecid Basde Complement Alternat Med, 2012:239638.
[7] MOTOMURA Y, GHIA J E, WANG H, et al.Enterochromaffin cell and 5-hydroxytryptamine responses to the same infectious agent differ in Th1 and Th2 dominant environments[J].Gut, 2008, 57:475-481.
[8] 胡乐义, 王巧民, 姜彬言, 等.肠易激综合征患者肠道菌群的变化及意义[J].安徽医科大学学报, 2012, 47(1):86-88.
[9] 胡瑞, 唐方.胃肠安丸对肠易激综合征大鼠血清电解质、VIP的影响[J].陕西中医, 2010, 31(7):914-916.
[10] 刘方, 王承党.肠道感染和肠道菌群与肠易激综合征[J].国际消化病杂志, 2008, 28(1):23-23.
-
计量
- 文章访问数: 94
- PDF下载数: 85
- 施引文献: 0
下载: